



**Lantheus**  
**Holdings**

**Corporate Presentation**

November 2019

---

# Safe Harbor Statements



## Important Information For Investors And Stockholders

This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws of such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

In connection with the proposed transaction, Lantheus Holdings intends to file with the Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 that will include a joint proxy statement of Lantheus Holdings and Progenics that also constitutes a prospectus of Lantheus Holdings. Each of Lantheus Holdings and Progenics also plan to file other relevant documents with the SEC regarding the proposed transaction. Any definitive joint proxy statement/prospectus (if and when available) will be mailed to stockholders of Lantheus Holdings and Progenics. INVESTORS AND SECURITY HOLDERS OF LANTHEUS HOLDINGS AND PROGENICS ARE STRONGLY ENCOURAGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (if and when available) and other documents filed with the SEC by Lantheus Holdings or Progenics through the website maintained by the SEC at <https://www.sec.gov>.

Copies of the documents filed with the SEC by Lantheus Holdings will also be available free of charge on Lantheus Holdings’ website at <https://www.lantheus.com/> or by contacting Lantheus Holdings’ Investor Relations Department by email at [ir@lantheus.com](mailto:ir@lantheus.com) or by phone at (978) 671-8001. Copies of the documents filed with the SEC by Progenics will also be available free of charge on Progenics’ internet website at <https://www.progenics.com/> or by contacting Progenics’ Investor Relations Department by email at [mdownloads@progenics.com](mailto:mdownloads@progenics.com) or by phone at (646) 975-2533.

## Certain Information Regarding Participants

Lantheus Holdings, Progenics, and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Lantheus Holdings is set forth in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on February 20, 2019, its definitive proxy statement for its 2019 annual meeting of stockholders, which was filed with the SEC on March 15, 2019, and its Current Report on Form 8-K, which was filed with the SEC on March 25, 2019. Other information regarding the participants of Lantheus Holdings in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available.

Information about the directors and executive officers of Progenics is set forth in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on March 15, 2019 and amended on April 30, 2019, and its definitive proxy statement for its 2019 annual meeting of stockholders, which was filed with the SEC on May 30, 2019. Other information regarding the participants of Progenics in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at <https://www.sec.gov> and from Investor Relations at Lantheus Holdings or Progenics as described above.

# Safe Harbor Statements



## Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current plans, estimates and expectations that are subject to various risks and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “target,” “contemplate,” “estimate,” “predict,” “potential,” “opportunity,” “creates” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including the expected timing of the closing of the merger; the ability of the parties to complete the merger considering the various closing conditions; the expected benefits of the merger, such as efficiencies, cost savings, synergies, revenue growth, creating shareholder value, growth potential, market profile, enhanced competitive position, and financial strength and flexibility; the competitive ability and position of the combined company; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Lantheus Holdings’ and Progenics’ plans, estimates or expectations could include, but are not limited to: (i) Lantheus Holdings or Progenics may be unable to obtain stockholder approval as required for the merger; (ii) conditions to the closing of the merger may not be satisfied; (iii) the merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement of the merger on the ability of Lantheus Holdings or Progenics to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Lantheus Holdings or Progenics does business, or on Lantheus Holdings’ or Progenics’ operating results and business generally; (v) Lantheus Holdings’ or Progenics’ respective businesses may suffer as a result of uncertainty surrounding the merger and disruption of management’s attention due to the merger; (vi) the outcome of any legal proceedings related to the merger; (vii) Lantheus Holdings or Progenics may be adversely affected by other economic, business, and/or competitive factors; (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (ix) risks that the merger disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger; (x) the risk that Lantheus Holdings or Progenics may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xi) risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, competitive and technological changes; (xiii) expectations for future clinical trials, the timing and potential outcomes of clinical studies and interactions with regulatory authorities; and (xiv) other risks to the consummation of the merger, including the risk that the merger will not be consummated within the expected time period or at all. Additional factors that may affect the future results of Lantheus Holdings and Progenics are set forth in their respective filings with the SEC, including each of Lantheus Holdings’ and Progenics’ most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC’s website at [www.sec.gov](http://www.sec.gov). Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that Lantheus Holdings and Progenics file from time to time with the SEC. The forward-looking statements in this document speak only as of the date of these materials. Except as required by law, Lantheus Holdings and Progenics assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

# The Lantheus Story



1

Market Leader  
Where We  
Are Today

2

Targeting  
Growing Markets

3

Enhancing Growth  
from a Position  
of Strength

4

Strong Capital  
Position To Fund  
Our Future



# Lantheus Overview



## Company Overview

- Global leader in the development, manufacture and commercialization of innovative medical diagnostics
- Portfolio of precision diagnostic products that help healthcare professionals identify disease and improve patient management
- DEFINITY® is the leading product in the ultrasound contrast market globally
  - Developing expanded indication (LVEF) and room temperature (RT) formulation
  - Pursuing additional applications of microbubbles outside of traditional contrast imaging
- Recognized innovator in the field of radiopharmaceutical diagnostics
  - Original innovator with first planar and SPECT radiopharmaceutical products, currently developing next-generation PET products

**#1 in Ultrasound Contrast Agents**

**Innovating in Microbubble applications**

**Leader in Radiopharmaceuticals**

**Pioneer in Radiopharmaceutical Diagnostics**


**Dynamic Pipeline**

**Across Microbubble and Radiopharmaceuticals**

**Operational Excellence**



**Manufacturing, Supply Chain and Commercial Expertise**

# A Legacy of Providing Best-in-Class Medical Diagnostic Products



# Leading Products and Market Share




Product Category	Revenue 2018*	% of Revenue*	Application	Key Product / U.S. Market Share**	Growth Rate***
	\$183M	53%	Injectable agent for echocardiograms	DEFINITY / ~80%	~18%
	\$160M	47%	Wide range of diagnostic imaging for cardiac perfusion, pulmonary function, cerebral blood flow, cancers	TechneLite / ~33%	Overall stable

\* Based on 2018 Worldwide Revenue (\$ in millions)  
 \*\* Source for DEFINITY market share: AMR Echocardiography Monthly Monitor, December 2018. Source for nuclear market share: LMI internal estimates.  
 \*\*\* 3-year CAGR




# A Corporate Footprint Balanced By Unique Core Competencies





# The Lantheus Story




# Large, Growing Global Markets



## Global Medical Imaging Market


(\$B)



Source: TechNavio, January 2017

## Global Radiopharmaceuticals Market

(\$B)




Source: TechNavio, April 2016

\* 5-year CAGR


# Large Echocardiography Market Opportunity – in the U.S. Alone

2% Annual Growth Rate in Total Echocardiograms



Currently, Lantheus has ~80% market share of contrast imaging agent use.

# The Lantheus Story



# Proposed Acquisition of Progenics: Compelling Strategic Rationale



**Robust portfolio and pipeline of precision diagnostic and therapeutic products**

**Driving strategic pipeline investments to capitalize on market opportunities and maximize returns**

**Sustainable and diversified revenue growth with focus on commercial execution excellence**

**Attractive financial profile and strengthened cash flow generation, with attention to cost synergy opportunities that support enhanced stockholder returns**

**Proven leadership with strong commercial, operational and financial expertise; aligned with stockholder interests**

# Transaction Summary



## Transaction Structure

- Lantheus Holdings to acquire 100% of Progenics' common shares structured in a tax-free all-stock transaction
- Progenics stockholders to receive 0.2502 Lantheus Holdings shares for each Progenics share
- Implies 21.5% premium to Progenics' 30-day volume weighted average closing stock price for the period ended October 1, 2019

## Ownership

- Lantheus stockholders to own approximately 65% of the combined company
- Progenics stockholders to own approximately 35% of the combined company

## Governance & Leadership

- Mary Anne Heino to remain Chief Executive Officer, Robert J. Marshall Jr. to remain Chief Financial Officer, and John Bolla to remain Chief Operations Officer
- Following the closing, Bradley Campbell, currently a member of Progenics' Board of Directors, will be added to the Board of Directors of Lantheus Holdings
- Continue to align Lantheus' compensation / accountability policies and programs with stockholders' interests

## Compelling Financial Rationale

- Diversifies revenue streams with additional marketed products, bolsters cash flow generation and positions company for sustainable long-term growth
- Approximately \$20 million in run-rate cost savings by 2022 related primarily to public company costs and G&A expense
- Accretive to Adjusted and Reported EPS by 2022 and 2023, respectively

## Timing and Approvals

- Transaction unanimously approved by Board of Directors of both companies
- Closing expected in the first quarter of 2020
- Transaction close subject to satisfaction of customary closing conditions, including receipt of regulatory and Lantheus and Progenics stockholder approvals



# Lantheus 2.0 Areas of Strategic Focus



## Lantheus 2.0 Vision

✓ Sustain and Accelerate Revenue Growth

✓ Diversified Portfolio of Diagnostics and Radiopharmaceutical Therapeutics

✓ Attractive Margins

✓ Global Reach

## Combination Creates a Leader in Microbubbles and Radiopharmaceuticals

Microbubbles

- Microbubble expansion strategy
- Assessment of potential direct adjacencies

## Pro Forma Product Portfolio



Nuclear 2.0 Diagnostics

- Fast growing PET segment driving precision diagnosis
- Increasing Pharma demand for nuclear imaging tracers and new isotopes for drug development
- Innovative use of AI to enhance diagnostic accuracy and prognostics



**Progenics Pharmaceuticals** *Combination creates a powerful leader in radiopharmaceutical theranostics*

Nuclear 2.0 Theranostics

- Use of nuclear medicine to diagnose and treat targeted diseases in oncology
- Precision diagnostics, enhanced by AI, guide targeted nuclear medicine therapy in oncology



Optical Imaging (Fluorescent Dye)

- Optical imaging reagent providing real time and accurate diagnosis
- Fluorescent dyes guiding clinical or surgical interventions


# Well-balanced Portfolio of Marketed Assets Spanning Diagnostics to Therapeutics



## Precision Diagnostics



**Xenon Xe 133 Gas**



### DEFINITY

- Benefits from unparalleled market and brand position
- Dedicated salesforce that drives advocacy and awareness
- Long-standing relationships with sonographers/echocardiologists
- New formulation has patent protection to 2035

### Radiopharmaceuticals

- Cardiolite recognized as most widely-used diagnostic product launched in the U.S. to date
- Wide range of diagnostic imaging for cardiac perfusion, pulmonary function, and cerebral blood flow
- Radiopharmaceutical business requires unique expertise including complex supply chain logistics

## Oncology



### AZEDRA

First/only FDA-approved treatment for adults and pediatric patients 12 and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheo/para who require systemic anticancer therapy

### RELISTOR

Only treatment with oral and subcutaneous formulations to treat opioid-induced constipation (OIC) in adults with chronic pain – targeted action treats the cause of OIC  
Licensed to Bausch Health

### QUADRAMET

Injectable radiopharmaceutical primarily used to treat pain associated with osteoblastic and mixed bone metastases confirmed on radionuclide bone scan

### Automated Bone Scan Index

Software as a medical device, is designed to quantify the disease burden in bone scans of metastatic prostate cancer patients

Complementary products position the combined company to better serve patients

# Robust Combined Pipeline with Clear Value Drivers



	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	FILING
<b>DEFINITY</b> <i>Octafluoropropane - Left Ventricular Ejection Fraction</i>	Life Cycle Management					
<b>DEFINITY</b> <i>Octafluoropropane - Room Temperature Formulation</i>	Life Cycle Management					
<b>Flurpiridaz F 18</b> <i>PET Myocardial Perfusion Imaging</i>	NCE Diagnostic					
<b>LMI 1195</b> <i>Flubromeguan - Neuroendocrine Tumors in Pediatric / Adult Populations</i>	NCE Diagnostic					
<b>Cerevast Retinal Vein Occlusion Technology</b> <i>Proprietary therapeutic ultrasound technology - Microbubble Franchise</i>	NCE Therapeutic					
<b>NM-01 <sup>99m</sup>Tc</b> <i>Anti-PD-L1 Biomarker Single-Domain Antibody</i>	NCE Diagnostic					
<b>PyL™ F 18</b> <i>PSMA-targeted PET / CT Imaging Agent</i>	NCE Diagnostic					
<b>1095 I-131</b> <i>PSMA-targeted Small Molecule Therapeutic</i>	NCE Therapeutic					
<b>1404 <sup>99m</sup>Tc</b> <i>PSMA-targeted SPECT / CT Imaging Agent</i>	NCE Diagnostic					
<b>PSMA TTC Th 227</b> <i>PSMA-targeted Conjugate Therapeutic</i>	NCE Therapeutic					
<b>PSMA AI</b> <i>Automated reading of PSMA images using AI</i>	Digital Solution					

Development Partners
<ul style="list-style-type: none"> <li>Lantheus developing</li> </ul>
<ul style="list-style-type: none"> <li>Lantheus developing</li> </ul>
<ul style="list-style-type: none"> <li>Lantheus in partnership with GE Healthcare<sup>1</sup></li> </ul>
<ul style="list-style-type: none"> <li>Lantheus developing</li> </ul>
<ul style="list-style-type: none"> <li>Lantheus partnership with Cerevast<sup>2</sup></li> </ul>
<ul style="list-style-type: none"> <li>Lantheus partnership with NanoMab<sup>3</sup></li> </ul>
<ul style="list-style-type: none"> <li>Progenics developing</li> <li>Licensed in Europe by Curium</li> </ul>
<ul style="list-style-type: none"> <li>Progenics developing</li> </ul>
<ul style="list-style-type: none"> <li>Licensed in Europe by ROTOP</li> </ul>
<ul style="list-style-type: none"> <li>Progenics partnership with Bayer<sup>4</sup></li> </ul>
<ul style="list-style-type: none"> <li>Progenics developing</li> </ul>

**Legend:** ■ NCE Precision Diagnostic ■ NCE Therapeutic  
▨ Life Cycle Management ■ Digital Solution

1. GE Healthcare is conducting the second phase 3 study.
2. Clinical development program conducted by Cerevast.
3. Ongoing Phase 1 clinical development conducted by NanoMab.
4. Clinical development program conducted by Bayer.

# Lantheus Merger with Progenics Will Create Value for All Shareholders



## Lantheus Track Record and Capabilities

Lantheus has a clear track record of creating significant shareholder value for its private equity and then public investors over the past 10 years

Lantheus long-term success is founded in in-house operational excellence, commercial expertise, financial discipline and robust corporate governance

Lantheus is uniquely capable to deploy its proven management team, accomplished Board of Directors and strong balance sheet to acquire, integrate and execute the Progenics transaction

## Well Positioned to Create Long-Term Shareholder Value

Lantheus enthusiastically shares the view of all Progenics shareholders in the long-term growth potential of the Progenics product portfolio

Importantly though, Lantheus, based on extensive due diligence, believes the next 12-18 months for Progenics are absolutely critical to maximizing the value of its portfolio and will require significant investment in capital, market-skilled resources, experienced decision-making and flawless execution

Lantheus' vision for integrating and executing on the Progenics transaction is value-creating for both Lantheus and Progenics' shareholders

# The Combination Of Lantheus And Progenics Accelerates Growth and Fuels Value Creation



<b>Profitable Double-Digit Revenue Growth</b>	<ul style="list-style-type: none"><li>▪ Diversify and further accelerate revenue growth while augmenting long-term margin and cash flows</li><li>▪ Achieve significant synergies and leverage established Lantheus infrastructure in nuclear medicine</li><li>▪ Achieve enhanced leadership position in radiopharmaceutical marketplace; leverage longstanding channel, customer and society relationships</li></ul>
<b>Two Near-Term Growth Drivers in AZEDRA and PyL</b>	<ul style="list-style-type: none"><li>▪ AZEDRA and PyL<sup>1</sup> can achieve ~\$150 million in 2023 net sales under Lantheus management</li><li>▪ Lantheus' established capabilities with radiopharmacy networks will accelerate PyL time to peak sales</li></ul>
<b>Synergy Between AZEDRA and 1195 in the Diagnosis and Treatment of Neuroendocrine Tumors</b>	<ul style="list-style-type: none"><li>▪ Combined company will have the pre-eminent diagnostic and radiopharmaceutical therapeutic for patients with norepinephrine-positive neuroendocrine tumors</li><li>▪ Potential enhanced clinical value through improved diagnostic accuracy; potential for better patient identification and management</li></ul>
<b>High-Potential Phase 2 Asset in 1095 Could Create Value in Near-Term</b>	<ul style="list-style-type: none"><li>▪ 1095 Phase 2 study underway with cost of &gt;\$30 million over the next two years<sup>2</sup></li><li>▪ Interim data readout from subset of patients could enable Phase 3 study initiation</li><li>▪ Progenics is targeting earlier stage prostate cancer patients for 1095 (versus Novartis' PSMA-617 therapeutic asset), which could create a differentiated position within a broader market</li><li>▪ Create competitive edge with the only fully-integrated radiopharmaceutical prostate portfolio: PyL, 1095, &amp; PSMA AI</li></ul>
<b>Attractive Near- and Medium-Term Financial Profile</b>	<ul style="list-style-type: none"><li>▪ Accretive to Adj. EBITDA in 2021 and Adj. EPS in 2022</li><li>▪ Approximately \$20 million run rate G&amp;A cost-savings starting in 2020 plus significant future cost avoidance</li><li>▪ Continued disciplined approach to spending across the business</li><li>▪ Well capitalized balance sheet enables investment in pipeline</li></ul>

1. If PyL is approved by the FDA in mid 2021 and assuming clinical study success and FDA approval for AZEDRA label expansion  
2. Based on Progenics operating as a standalone company

# Lantheus Uniquely Positioned to Drive Value with Progenics



## Optimize AZEDRA Go-to-Market Plan

- Lantheus ready to make critical investments of capital and talent to scale I-131 manufacturing in next 12-18 months
- Drive patient identification and pull through – reset the customer-facing model and deploy medical, advocacy and promotional resources
- Expand Lantheus operations efficiency toolkit to support centers of excellence for more rapid setup and efficient operations
- Use Lantheus customer service to improve the complex management process encompassing all logistics
- Improve timely and optimal patient treatment to ensure timely follow-up and appropriate patient / clinician support

## Maximize the Value of PyL Via Commercial Launch


- Significant investment and skilled execution required over the next 12-18 months to successfully launch PyL – critical path steps required in the first half of 2020
- Lantheus well positioned to:
  - ✓ Prepare the NDA by managing critical dependencies leading up to the NDA in Q3 2020
  - ✓ Set up PET radiopharmacy manufacturing facilities – guaranteeing reach into full target market for prostate cancer
  - ✓ Prepare the market by leveraging long-term relationship with radiopharmacy networks

## Committed to Investment in 1095

- Committed to advancing 1095 in an expeditious and financially-disciplined manner
- Lantheus team has developed mitigation plan to augment product availability for Phase II clinical trial, to accelerate US site setup, to drive patient enrollment, and to rapidly accrue data to inform the Phase III decision
- Considering all strategic options, including co-funding of the Phase III program, to realize the full value of 1095 within the integrated suite of prostate cancer products



# The Lantheus Story



# Strong Financial Outlook



<b>Gross Margins</b>	<ul style="list-style-type: none"><li>▪ Gross margin improvement potential through enhanced revenue growth and realizable cost savings and efficiencies</li><li>▪ Additional longer-term opportunities from diversified revenue / product mix</li></ul>
<b>EPS</b>	<ul style="list-style-type: none"><li>▪ Complementary portfolio of assets and realizable cost savings – expect to achieve approximately \$20 million in run-rate cost savings by 2022</li><li>▪ Accretion expected to be achieved in reasonable timeframe as high-value pipeline is commercialized</li><li>▪ Accretive to Adjusted and Reported EPS by 2022 and 2023, respectively</li></ul>
<b>Cash Flow</b>	<ul style="list-style-type: none"><li>▪ Enhanced free cash flow with improved top line growth, operational execution and expected synergy opportunities</li><li>▪ Strong liquidity position supports disciplined capital deployment</li></ul>
<b>Pro Forma ROIC</b>	<ul style="list-style-type: none"><li>▪ Strong and increasingly attractive ROIC metrics</li><li>▪ ROIC reaching double digits in year 2 and <math>\geq 20\%</math> thereafter</li></ul>
<b>Balance Sheet</b>	<ul style="list-style-type: none"><li>▪ Committed to returning to a leverage ratio of approximately 2.5x – 1.5x within two years</li><li>▪ Strong balance sheet provides financial flexibility</li></ul>

# Lantheus' Management Team Has the Experience to Integrate and Execute on the Acquisition of Progenics



## Strong Leadership

### Mary Anne Heino

*President, CEO and Director  
Lantheus Holdings*

- Joined Lantheus in April 2013 as Chief Commercial Officer and was promoted to Chief Operating Officer in March 2015, before becoming President and Chief Executive Officer in August 2015
- Fmr. President and SVP of World Wide Sales and Marketing at Angelini Labopharm LLC and Labopharm USA
- Fmr. VP of Strategic Planning and Competitive Intelligence and VP of Sales at Centocor, Inc., a Johnson & Johnson Company

### Robert Marshall

*Chief Financial Officer and  
Treasurer*

- Joined Lantheus in September 2018 as Chief Financial Officer and Treasurer
- Fmr. VP of Americas Finance and Corporate Treasurer of Zimmer Biomet Holdings
- Fmr. VP of Investor Relations and Treasurer of Zimmer Biomet Holdings

### John Bolla

*Chief Operations Officer*

- Joined Lantheus in May 2018 as SVP of Technical Operations and was promoted to Chief Operating Officer in March 2019
- Fmr. VP of Supply Chain, North America at GlaxoSmithKline
- Fmr. VP and Global Head of External Supply and Global Contract Manufacturing at GlaxoSmithKline

# Lantheus' Board Offers Diverse and Impressive Experience Base and Leadership Credentials in Commercial, Operations, R&D, M&A and Finance



## Diverse and Experienced Board of Directors

BOARD MEMBERS (EXCL. MANAGEMENT)	MOST RECENT ROLE	COMMERCIAL	OPERATIONAL	M&A	FINANCE	R&D	HCP
<b>Brian Markison</b> <i>(Chairman)</i> <sup>4</sup>	Chief Executive Officer, Osmotica Holdings, S.C.Sp	✓	✓	✓	✓	✓	
<b>James C. Clemmer</b> <sup>1,2</sup>	President and Chief Executive Officer, AngioDynamics Inc.	✓	✓	✓	✓	✓	
<b>Samuel Leno</b> <sup>1,4</sup>	Fmr. Executive Vice President and Chief Operations Officer, Boston Scientific		✓	✓	✓		
<b>Julie McHugh</b> <sup>2</sup>	Fmr. Chief Operating Officer, Endo Health Solutions, Inc.	✓	✓	✓	✓	✓	
<b>Gary J. Pruden</b> <sup>1,4</sup>	Fmr. Executive Vice President, Worldwide Chairman, Medical Devices, Johnson & Johnson	✓	✓	✓	✓	✓	
<b>Kenneth J. Pucel</b> <sup>2</sup>	Executive Vice President of Global Operations, Engineering & Lean, Polaris Industries Inc.		✓			✓	
<b>Dr. Frederick Robertson</b> <sup>1,3</sup>	Venture Partner, Baird Capital	✓	✓	✓	✓	✓	✓
<b>Dr. Derace Schaffer</b> <sup>2,3</sup>	Founder and Chief Executive Officer, The Lan Group		✓	✓		✓	✓
<b>Dr. James H. Thrall</b> <sup>3</sup>	Distinguished Juan M. Taveras Professorship of Radiology, Harvard Medical School					✓	✓

1. Audit Committee member
2. Compensation Committee member
3. Nominating and Corporate Governance Committee member
4. Financing and Strategy Committee member



**Lantheus**  
**Holdings**

**Corporate Presentation**

November 2019

---